Appetite Stimulant Market Report 2026

The appetite stimulant market size has grown strongly in recent years. It will grow from $1.9 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to malnutrition prevalence, chronic illness burden, oncology supportive care usage, geriatric population growth, hospital nutrition programs.

The appetite stimulant market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to personalized nutrition demand, homecare treatment expansion, functional food innovation, appetite loss management, chronic disease survival rates. Major trends in the forecast period include growing use in chronic disease management, increased adoption in geriatric nutrition, rising preference for natural appetite stimulants, expansion of functional food-based formulations, growth of homecare nutritional support.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the appetite stimulant market in the coming years. A chronic disease refers to a long-term medical condition or illness that typically persists for three months or longer and often progresses over time. The growing incidence of chronic diseases is largely linked to poor dietary habits, as unhealthy eating patterns, including high intake of processed foods, sugars, and unhealthy fats, contribute to conditions such as obesity, diabetes, and cardiovascular diseases. Appetite stimulants support the management of chronic diseases by improving nutritional status and overall health outcomes through increased hunger and food intake, which can help individuals gain or maintain body weight. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, non-communicable diseases (NCDs), also known as chronic diseases, accounted for 41 million deaths annually worldwide, representing 74% of all deaths. These included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is contributing to the growth of the appetite stimulant market.

Major companies operating in the appetite stimulant market are emphasizing the promotion of innovative offerings such as ayurvedic appetite stimulants to appeal to health-conscious consumers. An ayurvedic appetite stimulant is a natural formulation derived from traditional herbs that supports appetite enhancement by stimulating digestive fire, improving enzyme secretion, and aiding better nutrient absorption. For instance, in October 2024, Lupin Limited, an India-based pharmaceutical company, announced the launch of its Aptivate Achi Bhookh Fest to encourage healthy eating practices and raise nutrition awareness among children through interactive programs and expert-led sessions, with plans to extend the campaign to reach 250,000 individuals across schools and residential communities. Aptivate is an ayurvedic appetite stimulant for children developed to assist parents in fostering healthy eating habits. The product plays a significant role in LupinLife’s initiatives, including the Aptivate Achi Bhookh Fest, which promotes optimal nutrition and strong immunity among children.

In January 2025, Zuellig Pharma Corporation, a Singapore-based company focused on healthcare distribution and pharmaceutical solutions, acquired Propan from ADP Pharma Corporation for an undisclosed sum. Through this acquisition, Zuellig Pharma seeks to reinforce its presence in the consumer health segment by broadening its portfolio with a well-established appetite stimulant and multivitamin brand, thereby strengthening its capability to provide high-quality healthcare solutions tailored to the varied nutritional requirements of different age groups. ADP Pharma Corporation is a Philippines-based pharmaceutical company that specializes in appetite stimulants.

Major companies operating in the appetite stimulant market are Bristol Myers Squibb, Novartis AG, Solvay Pharmaceuticals, Lupin Limited, TIL Healthcare Private Limited, Zeon Lifesciences Limited, Apex Laboratories Private Limited, Nuray Chemicals Private Limited, Arlak Biotech Private Limited, AdvaCare Pharma USA LLC, Dwarkesh Pharmaceuticals Private Limited, Par Pharmaceutical Companies Inc., Salvus Healthcare Private Limited, Epitome Pharmaceuticals Private Limited, Abiba Pharmacia Private Limited, Pharmika India Private Limited, Wellona Pharma, SiNi Pharma, Vibcare Pharma Private Limited, Mayons Pharmaceuticals Private Limited.

North America was the largest region in the appetite stimulant market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the appetite stimulant market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the appetite stimulant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the appetite stimulant market by increasing the cost of imported active pharmaceutical ingredients, herbal extracts, and formulation excipients used in appetite-enhancing products. These impacts have been most pronounced in prescription and natural stimulant segments, particularly in north america and europe where ingredient sourcing is globally diversified. Asia-pacific manufacturers have faced raw material price volatility. However, tariffs have encouraged domestic production of herbal and OTC appetite stimulants.

The appetite stimulant market research report is one of a series of new reports that provides appetite stimulant market statistics, including appetite stimulant industry global market size, regional shares, competitors with a appetite stimulant market share, detailed appetite stimulant market segments, market trends and opportunities, and any further data you may need to thrive in the appetite stimulant industry. This appetite stimulant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Appetite stimulants refer to substances or products developed to enhance an individual’s appetite, especially when hunger is reduced due to medical conditions, treatments, or other contributing factors. These stimulants act on hormones or brain mechanisms that regulate hunger signals, thereby increasing the urge to eat.

The primary categories of appetite stimulants include prescription, over-the-counter, and natural options. Prescription appetite stimulants are medications administered under medical guidance to increase hunger in individuals suffering from significant appetite loss associated with conditions such as cancer, HIV/AIDS, or chronic illnesses. These stimulants are offered in multiple forms, including liquid formulations, powder formulations, capsules and tablets, as well as functional foods. They are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized by diverse end-users such as hospitals, homecare providers, and specialty centers.

The appetite stimulant market consists of sales of cyproheptadine, mirtazapine, and anamorelin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.